Increased risk of chronic fatigue syndrome following infection: a 17-year population-based cohort study.
Chang, Hsun, Kuo, Chien-Feng, Yu, Teng-Shun et al. · Journal of translational medicine · 2023 · DOI
Quick Summary
This large study from Taiwan tracked nearly 400,000 people over 17 years to see if getting an infection increased their chances of developing ME/CFS. Researchers found that people who had certain infections—including chickenpox, tuberculosis, flu, and common bacterial infections—were about 1.5 times more likely to develop ME/CFS compared to people without these infections. Interestingly, people who took certain antibiotics had lower rates of ME/CFS, suggesting that some infections may trigger ME/CFS in some people.
Why It Matters
This study provides population-level evidence supporting the clinical observation that ME/CFS often emerges following acute infections, potentially validating infection as an important trigger or risk factor. The finding that specific pathogens and antibiotic treatments correlate with CFS risk may inform future research into mechanisms of post-infectious ME/CFS and guide clinical investigation strategies.
Observed Findings
People with documented infections had an incidence rate of 5.40 CFS cases per 1,000 person-years, compared to 3.67 per 1,000 person-years in the non-infected population.
Seven specific pathogens showed statistically significant associations with increased CFS risk: varicella-zoster virus, Mycobacterium tuberculosis, Escherichia coli, Candida, Salmonella, Staphylococcus aureus, and influenza virus.
Patients prescribed doxycycline, azithromycin, moxifloxacin, levofloxacin, or ciprofloxacin exhibited significantly lower CFS incidence compared to matched controls.
The overall adjusted hazard ratio for infection-associated CFS risk was 1.5 (95% CI 1.47–1.54), indicating a 50% increased risk.
Inferred Conclusions
Infection with common bacterial and viral pathogens is associated with increased risk of developing ME/CFS in the general population.
Certain antibiotic exposures may have a protective effect against subsequent CFS development, though the mechanism remains unclear.
Infection should be considered a potential trigger or risk factor for ME/CFS, particularly when infections precede symptom onset.
Remaining Questions
What is the biological mechanism by which specific infections trigger or predispose to ME/CFS development in some individuals but not others?
Why do certain antibiotics appear protective—are they reducing pathogen burden, modifying the microbiome, or affecting immune responses in ways that prevent CFS?
What This Study Does Not Prove
This study establishes correlation, not causation—infection does not necessarily cause ME/CFS, and other unmeasured factors may explain the association. The study cannot determine why certain infections increase CFS risk or whether infection directly triggers disease pathology versus simply marking a susceptible subpopulation. The protective effect of certain antibiotics requires further investigation and does not prove these drugs prevent ME/CFS.
What is the temporal relationship between infection resolution and ME/CFS onset, and are there early markers predicting who will develop CFS after infection?
Do genetic or immunological differences explain individual variation in CFS risk following similar infections?